Jiazi Yu1,2, John Zhang3,4, Tao Peng1,2, Zhenglei Fei1,2, Liangbin Jin1,2, Mian Yang5,2. 1. Department of General Surgery, Ningbo Medical Treatment Centre Li Huili Hospital, Ningbo, P.R. China. 2. Li Huili Hospital of Ningbo University, Ningbo, P.R. China. 3. Thayer School of Engineering, Dartmouth College, Engineering Drive, Hanover, NH, U.S.A. 4. Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Hanover, NH, U.S.A. 5. Department of General Surgery, Ningbo Medical Treatment Centre Li Huili Hospital, Ningbo, P.R. China; 939838409@qq.com.
Abstract
BACKGROUND/AIM: Insufficient data exist to support the concept of the circulating tumor cell (CTC) level as a prognostic factor for platinum-based first-line chemotherapy. This study investigated the impact of CTCs on the prognosis of patients with advanced colorectal cancer (CRC) after receiving platinum-based chemotherapy. Analyses were carried out of clinicopathological features and molecular phenotypes to clarify independent risk factors for a high CTC count. PATIENTS AND METHODS: Patients diagnosed with stage III/IV CRC (n=76) were included in the study. The blood samples of patients were evaluated for CTCs using the CellRich™ platform system. Immunohistochemistry (Ias used to analyze epithelial-mesenchymal transition-associated biomarkers E-cadherin and vimentin. Univariate and logistic regression analyses were then conducted to analyze the risk factors for CTC expression. Additionally, the influence of oxaliplatin on disease-free survival after first-line chemotherapy or during chemotherapy was analyzed through a 2-year follow-up. RESULTS: Patients in the CTC+ group experienced shorter DFS after receiving oxaliplatin first-line chemotherapy than patients in the CTC- group (p<0.01). In addition, univariate analysis revealed that the tumor M-stage, tumor location, RAS mutation, high expression of vimentin, and deletion of E-cadherin expression were correlated with a high CTC count. Multivariate analysis suggested that the presence of RAS gene mutations and high vimentin expression were independent risk factors for high CTC loads (p<0.01). CONCLUSION: CTC positivity can indicate the efficacy of first-line chemotherapy with oxaliplatin in stage III/IV colorectal cancer. This may be linked to tumor epithelial-mesenchymal transition in patients with CTCs. Moreover, RAS gene mutation and high expression of vimentin were identified as independent risk factors for a high CTC count. Copyright
BACKGROUND/AIM: Insufficient data exist to support the concept of the circulating tumor cell (CTC) level as a prognostic factor for platinum-based first-line chemotherapy. This study investigated the impact of CTCs on the prognosis of patients with advanced colorectal cancer (CRC) after receiving platinum-based chemotherapy. Analyses were carried out of clinicopathological features and molecular phenotypes to clarify independent risk factors for a high CTC count. PATIENTS AND METHODS: Patients diagnosed with stage III/IV CRC (n=76) were included in the study. The blood samples of patients were evaluated for CTCs using the CellRich™ platform system. Immunohistochemistry (Ias used to analyze epithelial-mesenchymal transition-associated biomarkers E-cadherin and vimentin. Univariate and logistic regression analyses were then conducted to analyze the risk factors for CTC expression. Additionally, the influence of oxaliplatin on disease-free survival after first-line chemotherapy or during chemotherapy was analyzed through a 2-year follow-up. RESULTS: Patients in the CTC+ group experienced shorter DFS after receiving oxaliplatin first-line chemotherapy than patients in the CTC- group (p<0.01). In addition, univariate analysis revealed that the tumor M-stage, tumor location, RAS mutation, high expression of vimentin, and deletion of E-cadherin expression were correlated with a high CTC count. Multivariate analysis suggested that the presence of RAS gene mutations and high vimentin expression were independent risk factors for high CTC loads (p<0.01). CONCLUSION: CTC positivity can indicate the efficacy of first-line chemotherapy with oxaliplatin in stage III/IV colorectal cancer. This may be linked to tumor epithelial-mesenchymal transition in patients with CTCs. Moreover, RAS gene mutation and high expression of vimentin were identified as independent risk factors for a high CTC count. Copyright
Authors: T Yoshino; D Arnold; H Taniguchi; G Pentheroudakis; K Yamazaki; R-H Xu; T W Kim; F Ismail; I B Tan; K-H Yeh; A Grothey; S Zhang; J B Ahn; M Y Mastura; D Chong; L-T Chen; S Kopetz; T Eguchi-Nakajima; H Ebi; A Ohtsu; A Cervantes; K Muro; J Tabernero; H Minami; F Ciardiello; J-Y Douillard Journal: Ann Oncol Date: 2018-01-01 Impact factor: 32.976
Authors: S J Cohen; C J A Punt; N Iannotti; B H Saidman; K D Sabbath; N Y Gabrail; J Picus; M A Morse; E Mitchell; M C Miller; G V Doyle; H Tissing; L W M M Terstappen; N J Meropol Journal: Ann Oncol Date: 2009-03-12 Impact factor: 32.976
Authors: J Tol; M Koopman; M C Miller; A Tibbe; A Cats; G J M Creemers; A H Vos; I D Nagtegaal; L W M M Terstappen; C J A Punt Journal: Ann Oncol Date: 2009-10-27 Impact factor: 32.976
Authors: Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol Journal: J Clin Oncol Date: 2008-07-01 Impact factor: 44.544